<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>299</serviceExecutionTime><Drug id="10001"><DrugName>T-794</DrugName><DrugSynonyms><Name><Value>T-94</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>T-794</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>135204-83-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20315">Tanabe Seiyaku Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Company id="20315">Tanabe Seiyaku Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10001" type="Drug"><TargetEntity id="219317" type="siDrug">T-794</TargetEntity></SourceEntity><SourceEntity id="20289" type="Company"><TargetEntity id="4295876967" type="organizationId">Taisho Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20315" type="Company"><TargetEntity id="4298123051" type="organizationId">Nipro ES Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="254" type="Action"><TargetEntity id="449" type="Mechanism">MAO-A Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01273" type="ciTarget"><TargetEntity id="175834908241283" type="siTarget">Amine oxidase [flavin-containing] A</TargetEntity><TargetEntity id="9251" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="254">MAO A inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2004-03-24T23:48:00.000Z</LastModificationDate><ChangeDateLast>2004-03-24T23:48:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Tanabe is investigating &lt;ulink linkType="Drug" linkID="10001"&gt;T-794&lt;/ulink&gt;, a reversible selective inhibitor of monoamine oxidase-A (MAO-A), for the potential treatment of depression [&lt;ulink linkType="reference" linkID="175549"&gt;175549&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;It is effective in animal models of antidepressant activity, causing no weight loss, and is more potent and selective for MAO-A than &lt;ulink linkType="Drug" linkID="3644"&gt;moclobemide&lt;/ulink&gt; (qv) [&lt;ulink linkType="reference" linkID="175549"&gt;175549&lt;/ulink&gt;]. It also shows no evidence of cholinergic activity and a much reduced interaction with tyramine as compared to older MAO inhibitors [&lt;ulink linkType="reference" linkID="285978"&gt;285978&lt;/ulink&gt;]. The compound displayed an IC50 value of 3.8 nM against MAO-A [&lt;ulink linkType="reference" linkID="296669"&gt;296669&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Taisho is the licensee in Japan [&lt;ulink linkType="reference" linkID="251978"&gt;251978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Compounds of this type are disclosed in EP-00425209.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2001-08-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2001-08-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="175549" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><Source id="175549" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01273"><Name>MAO A</Name><SwissprotNumbers><Swissprot>O18851</Swissprot><Swissprot>P21396</Swissprot><Swissprot>P21397</Swissprot><Swissprot>P21398</Swissprot><Swissprot>P58027</Swissprot><Swissprot>Q5NU32</Swissprot><Swissprot>Q5RE60</Swissprot><Swissprot>Q64133</Swissprot><Swissprot>Q6Q2J0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>COC[C@H]1CN(C(=O)O1)c2ccc3cc(ccc3c2)OCC4CC4</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug><Drug id="100019"><DrugName>HOB-071</DrugName><DrugSynonyms><Name><Value>HOB-071</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DPP-IV + ARB (diabetic hyperlipidemia), Hyundai Pharma</Value></Name></DrugSynonyms><CompanyOriginator id="22606">Hyundai Pharmaceutical</CompanyOriginator><CompaniesSecondary><Company id="22606">Hyundai Pharmaceutical</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22606" type="Company"><TargetEntity id="4295881051" type="organizationId">Hyundai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"/><TargetEntity id="D006949" type="MeSH"/><TargetEntity id="-1908196798" type="omicsDisease"/><TargetEntity id="971" type="siCondition"/></SourceEntity><SourceEntity id="64" type="Action"><TargetEntity id="3578" type="Mechanism">Anti-Angiotensin II</TargetEntity></SourceEntity><SourceEntity id="5537" type="Action"><TargetEntity id="5399" type="Mechanism">Dipeptidyl peptidase 4 (DPP4) antagonists</TargetEntity><TargetEntity id="3328" type="Mechanism">Anti-CD26 (Anti-Dipeptidyl Peptidase IV; DPPIV)</TargetEntity><TargetEntity id="415" type="Mechanism">Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00618" type="ciTarget"><TargetEntity id="17367845618033" type="siTarget">Dipeptidyl peptidase 4</TargetEntity><TargetEntity id="8056" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="175">Hyperlipidemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="64">Angiotensin II receptor antagonist</Action><Action id="5537">Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C9C</Code><Name>ANGIOTENSIN-II ANTAGONISTS, PLAIN</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:20:11.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="22606" linkType="Company"&gt;Hyundai Pharma&lt;/ulink&gt; was investigating HOB-071, a dipeptidyl peptidase-IV (DPP-IV) inhibitor and an angiotensin II receptor antagonist (ARB), for the potential treatment of diabetic hyperlipidemia [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;]. In November 2015, the program was in the discovery stage [&lt;ulink linkID="1710896" linkType="Reference"&gt;1710896&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22606">Hyundai Pharmaceutical</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-11-06T00:00:00.000Z</StatusDate><Source id="1710896" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00139"><Name>Angiotensin II receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00618"><Name>Dipeptidyl peptidase IV</Name><SwissprotNumbers><Swissprot>P14740</Swissprot><Swissprot>P22411</Swissprot><Swissprot>P27487</Swissprot><Swissprot>P28843</Swissprot><Swissprot>P81425</Swissprot><Swissprot>Q9N2I7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1710896" linkType="reference" linkID="1710896"&gt;1710896&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>